New treatments for age-related macular degeneration

Lancet

Volumn 370, Issue 9597, 2007, Pages 1481-

  Taylor, Hugh R ^a   Pezzullo, M Lynne ^a   Guymer, Robyn ^a  

^a CENTRE FOR EYE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AUSTRALIA; BLINDNESS; DRUG COST; DRUG EFFICACY; GOVERNMENT; HUMAN; LETTER; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROFIT; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; RISK REDUCTION; COST BENEFIT ANALYSIS; ECONOMICS; FEE; NOTE; RETINA MACULA DEGENERATION; STATISTICAL MODEL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; HUMANS; MACULAR DEGENERATION; MODELS, ECONOMIC; PRESCRIPTION FEES;

EID: 35448940862     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61628-6     Document Type: Letter

References (2)

1. The Lancet. Macular degeneration, patients' groups, and pharma. Lancet 370 (2007) 194
2. Eye Research Australia. Centrally focussed: the impact of age-related macular degeneration. A dynamic economic model and report by Access Economics Pty Limited (2006), Centre for Eye Research Australia, Melbourne. http://www.cera.org.au/publications/cent_focus.html (accessed Sept 19, 2007).